-
Je něco špatně v tomto záznamu ?
Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system
A. Delimitsou, F. Fostira, D. Kalfakakou, P. Apostolou, I. Konstantopoulou, C. Kroupis, AG. Papavassiliou, Z. Kleibl, E. Stratikos, GE. Voutsinas, D. Yannoukakos,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
A.G. Leventis Foundation - International
IKY_Greek State Scholarships Foundation - International
P. BROCA
research program ARISTEIA - International
ARISTEIA 39
research program ARISTEIA - International
European Union (European Social Fund, ESF) - International
Greek national funds through the Operational Program - International
MIS 5002514
Target Identification and Development of Novel Approaches for Health and Environmental Applications - International
NSRF 2014-2020
Competitiveness, Entrepreneurship and Innovation - International
Greece and the European Union (European Regional Development Fund) - International
PubMed
30851065
DOI
10.1002/humu.23728
Knihovny.cz E-zdroje
- MeSH
- alely MeSH
- checkpoint kinasa 2 genetika metabolismus MeSH
- frekvence genu MeSH
- genetická predispozice k nemoci MeSH
- genetické asociační studie MeSH
- konformace proteinů MeSH
- lidé MeSH
- molekulární modely MeSH
- mutace * MeSH
- rodokmen MeSH
- Saccharomyces cerevisiae genetika metabolismus MeSH
- substituce aminokyselin MeSH
- výpočetní biologie metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Genetic testing for cancer predisposition leads to the identification of a number of variants with uncertain significance. To some extent, variants of BRCA1/2 have been classified, in contrast to variants of other genes. CHEK2 is a typical example, in which a large number of variants of unknown clinical significance were identified and still remained unclassified. Herein, the CHEK2 variant assessment was performed through an in vivo, yeast-based, functional assay. In total, 120 germline CHEK2 missense variants, distributed along the protein sequence, and two large in-frame deletions were tested, originating from genetic test results in breast cancer families, or selected from the ClinVar database. Of these, 32 missense and two in-frame deletions behaved as non-functional, 73 as functional, and 15 as semi-functional, after comparing growth rates of each strain with positive and negative controls. The majority of non-functional variants were localized in the CHK2 kinase and forkhead-associated domains. In vivo results from the non-functional variants were in agreement with in silico predictions, and, where available, with strong breast cancer family history, to a great extent. The results of the largest, to date, yeast-based assay, evaluating CHEK2 variants, can complement and assist in the classification of rare CHEK2 variants with unclear clinical significance.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006542
- 003
- CZ-PrNML
- 005
- 20200521090415.0
- 007
- ta
- 008
- 200511s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/humu.23728 $2 doi
- 035 __
- $a (PubMed)30851065
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Delimitsou, Angeliki $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece. Laboratory of Environmental Mutagenesis and Carcinogenesis, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece.
- 245 10
- $a Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system / $c A. Delimitsou, F. Fostira, D. Kalfakakou, P. Apostolou, I. Konstantopoulou, C. Kroupis, AG. Papavassiliou, Z. Kleibl, E. Stratikos, GE. Voutsinas, D. Yannoukakos,
- 520 9_
- $a Genetic testing for cancer predisposition leads to the identification of a number of variants with uncertain significance. To some extent, variants of BRCA1/2 have been classified, in contrast to variants of other genes. CHEK2 is a typical example, in which a large number of variants of unknown clinical significance were identified and still remained unclassified. Herein, the CHEK2 variant assessment was performed through an in vivo, yeast-based, functional assay. In total, 120 germline CHEK2 missense variants, distributed along the protein sequence, and two large in-frame deletions were tested, originating from genetic test results in breast cancer families, or selected from the ClinVar database. Of these, 32 missense and two in-frame deletions behaved as non-functional, 73 as functional, and 15 as semi-functional, after comparing growth rates of each strain with positive and negative controls. The majority of non-functional variants were localized in the CHK2 kinase and forkhead-associated domains. In vivo results from the non-functional variants were in agreement with in silico predictions, and, where available, with strong breast cancer family history, to a great extent. The results of the largest, to date, yeast-based assay, evaluating CHEK2 variants, can complement and assist in the classification of rare CHEK2 variants with unclear clinical significance.
- 650 _2
- $a alely $7 D000483
- 650 _2
- $a substituce aminokyselin $7 D019943
- 650 _2
- $a checkpoint kinasa 2 $x genetika $x metabolismus $7 D064447
- 650 _2
- $a výpočetní biologie $x metody $7 D019295
- 650 _2
- $a frekvence genu $7 D005787
- 650 _2
- $a genetické asociační studie $7 D056726
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a molekulární modely $7 D008958
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a rodokmen $7 D010375
- 650 _2
- $a konformace proteinů $7 D011487
- 650 _2
- $a Saccharomyces cerevisiae $x genetika $x metabolismus $7 D012441
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Fostira, Florentia $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
- 700 1_
- $a Kalfakakou, Despoina $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
- 700 1_
- $a Apostolou, Paraskevi $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
- 700 1_
- $a Konstantopoulou, Irene $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
- 700 1_
- $a Kroupis, Christos $u Department of Clinical Biochemistry, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- 700 1_
- $a Papavassiliou, Athanasios G $u Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- 700 1_
- $a Kleibl, Zdenek $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Stratikos, Efstratios $u Protein Chemistry Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
- 700 1_
- $a Voutsinas, Gerassimos E $u Laboratory of Environmental Mutagenesis and Carcinogenesis, Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece.
- 700 1_
- $a Yannoukakos, Drakoulis $u Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research "Demokritos", Athens, Greece.
- 773 0_
- $w MED00002078 $t Human mutation $x 1098-1004 $g Roč. 40, č. 5 (2019), s. 631-648
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30851065 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200521090412 $b ABA008
- 999 __
- $a ok $b bmc $g 1525400 $s 1096598
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 40 $c 5 $d 631-648 $e 20190309 $i 1098-1004 $m Human mutation $n Hum Mutat $x MED00002078
- GRA __
- $p A.G. Leventis Foundation $2 International
- GRA __
- $p IKY_Greek State Scholarships Foundation $2 International
- GRA __
- $a P. BROCA $p research program ARISTEIA $2 International
- GRA __
- $a ARISTEIA 39 $p research program ARISTEIA $2 International
- GRA __
- $p European Union (European Social Fund, ESF) $2 International
- GRA __
- $p Greek national funds through the Operational Program $2 International
- GRA __
- $a MIS 5002514 $p Target Identification and Development of Novel Approaches for Health and Environmental Applications $2 International
- GRA __
- $a NSRF 2014-2020 $p Competitiveness, Entrepreneurship and Innovation $2 International
- GRA __
- $p Greece and the European Union (European Regional Development Fund) $2 International
- LZP __
- $a Pubmed-20200511